Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.54 |
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25003135 | 0.86 | ALDH1A1 (0.61) | KDM5BKDM5AKDM2BKDM4CALDH1A1 | |
| SCHEMBL1758329 | 0.85 | KDM1A (0.55) | PARP10CHEK2KDM5BKDM5AKDM2B | |
| SCHEMBL25002925 | 0.84 | NPC1 (0.59) | KDM5BKDM5AKDM2BKDM4CALDH1A1 | |
| SCHEMBL29932995 | 0.80 | MAP4K4 (0.54) | CHEK2KDM5BKDM2BKDM4CKMT2A | |
| SCHEMBL1758360 | 0.80 | PARP10 (0.57) | PARP10CHEK2KDM5BALDH1A1KMT2A | |
| SCHEMBL6679157 | 0.80 | SMN1; SMN2 (0.48) | KDM5BKDM2BKDM4CALDH1A1KDM4E | |
| SCHEMBL1758373 | 0.79 | SCN9A (0.57) | PARP10CHEK2KDM5BMAP4K4KDM4B | |
| SCHEMBL1758489 | 0.79 | SCN10A (0.62) | CHEK2KDM5BKDM5AKDM2BKDM4C | |
| SCHEMBL29932888 | 0.79 | MAP4K4 (0.55) | CHEK2KDM5BKMT2AMAPTMAP4K4 | |
| SCHEMBL28907344 | 0.79 | KDM4B (0.56) | CHEK2KDM5BKDM4CALPLMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | disclosed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | PARP10 2411/4885CHEK2 4679/4885KDM5B 1924/4885 |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | CACNA1S, CACNA1E, CACNA1C | PARP10 2285/4885CHEK2 4653/4885KDM5B 1977/4885 |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | PARP10 3325/4885CHEK2 4843/4885KDM5B 1870/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | PARP10 2411/4885CHEK2 4679/4885KDM5B 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.